DEF: Aditxt Seeks Shareholder Approval for Reverse Split, Name Change, and Equity Plans

Aditxt, Inc. calls a Special Meeting to approve a reverse stock split, a corporate name change to bitXbio, Inc., and the issuance of shares related to past financings and new employee equity plans.

Summary

• Stockholders are invited to a Special Meeting on January 30, 2026, to vote on eight proposals, including approvals for past equity issuances, new employee incentive plans, a corporate name change, and a reverse stock split.
• Proposal 1 seeks approval for the issuance of common stock underlying 22,280 shares of Series A-1 Convertible Preferred Stock, originally issued in December 2023, with a conversion price of $4.44 per share (subject to adjustment, with a floor of $0.888 or 80% VWAP).
• Proposal 2 seeks approval for the issuance of common stock underlying 10,853 shares of Series C-1 Convertible Preferred Stock (issued May 2024) with a conversion price of $2.595 per share (subject to adjustment, with a floor of $0.519 or 80% VWAP), and common stock purchase warrants issued in May and August 2024 with initial exercise prices of $2,791,100.00 and $586,470.00 per share, respectively.
• Proposal 3 seeks approval for the issuance of common stock underlying common stock purchase warrants issued in July 2024, related to $1.5 million in senior notes, with an exercise price of $1.582 per share (subject to adjustment, with a floor of $0.295).
• These approvals (Proposals 1, 2, 3) are required by Nasdaq Marketplace Rule 5635(d) due to the potential issuance of 20% or more of outstanding common stock at a price less than market.
• Proposal 4 requests approval for the 2025 Employee Stock Purchase Plan (ESPP), reserving an initial 200,000 shares of common stock, with annual increases up to 1% of outstanding common stock (maximum 400,000 total shares). Employees can purchase shares at a discount of not less than 85% of the fair market value.
• Proposal 5 proposes an amendment to the 2021 Omnibus Equity Incentive Plan to increase the number of shares issuable thereunder from 3 to 350,000 shares, representing approximately 19.7% of current common stock.
• Proposal 6 is a non-binding advisory vote to change the company's corporate name from Aditxt, Inc. to bitXbio, Inc., to better align with its evolving strategy integrating blockchain, Fintech, and AI technologies with life sciences.
• Proposal 7 seeks to grant discretionary authority to the board of directors to effect a reverse stock split at a ratio between one-for-five (1:5) and one-for-two hundred fifty (1:250) within one year, primarily to increase the per-share market price and regain compliance with Nasdaq's continued listing requirements.
• Proposal 8 authorizes the adjournment of the Special Meeting if necessary to solicit additional proxies.
• As of the record date, December 5, 2025, there were 1,776,023 shares of common stock outstanding, requiring a quorum of 592,008 shares.

Sentiment

Score: 3

Explanation: The filing outlines several proposals, including a reverse stock split and approvals for past dilutive financings, which are typically signs of a company facing significant challenges with its stock valuation and capital structure. While new employee incentive plans and a strategic name change are positive in intent, they do not outweigh the underlying financial weakness implied by the need for such extensive restructuring and past dilutive activities. The extremely high nominal initial exercise prices for some warrants in the proposal summaries, even if subject to adjustment, highlight a history of complex and potentially unfavorable financing terms for common shareholders.

Positives

• The introduction of the 2025 Employee Stock Purchase Plan (ESPP) and the expansion of the 2021 Omnibus Equity Incentive Plan are designed to attract, motivate, and retain key employees and non-employee directors, aligning their interests with the company's long-term success.
• The proposed name change to bitXbio, Inc. reflects a strategic evolution to integrate digital innovation (blockchain, Fintech, AI) with life sciences, potentially broadening the company's scope and capitalization strategies.
• Seeking stockholder approval for past equity issuances ensures compliance with Nasdaq listing rules, which is essential for maintaining the company's public market access and avoiding potential delisting.

Negatives

• The necessity of seeking stockholder approval for past issuances of preferred stock and warrants (Series A-1, Series C-1, July Warrants) under Nasdaq rules indicates that these were dilutive financing activities conducted at prices below market value at the time of agreement.
• The proposed reverse stock split, with a wide range of 1:5 to 1:250, is a strong indicator of a severely depressed common stock price, likely below Nasdaq's minimum bid price requirement, and is often viewed negatively by the market.
• The potential for significant dilution from the conversion of preferred stock and exercise of warrants, as well as the increased shares for the equity incentive plan, will dilute the voting power and economic rights of existing common stockholders.
• The company does not anticipate paying cash dividends on its common stock in the foreseeable future, indicating a continued focus on reinvestment rather than direct shareholder returns.
• The extremely high initial exercise prices for some warrants (e.g., $2,791,100.00 and $586,470.00 per share) mentioned in the proposal background, even if subject to adjustment, highlight a history of complex and potentially unfavorable financing terms for common shareholders.

Risks

• Issuance of common stock upon conversion of preferred stock and exercise of warrants will have a dilutive effect on existing stockholders, potentially reducing their voting power and economic rights.
• The additional shares issuable could lead to a decline in the common stock's share price or greater price volatility.
• There is no assurance that the reverse stock split, if completed, will result in the intended benefits, such as a sustained increase in market price or regaining/maintaining Nasdaq listing compliance.
• A reverse stock split may be perceived negatively by investors, analysts, and other market participants, potentially leading to further stock price declines.
• A reduced number of outstanding shares after a reverse stock split could adversely affect the liquidity of the common stock.
• Failure to obtain stockholder approval for the ESPP and Equity Incentive Plan proposals could adversely affect the company's ability to recruit, retain, and incentivize top talent.
• Triggering events for preferred stock, such as trading suspension, failure to remove restrictive legends, default on $500,000 or more of indebtedness, bankruptcy proceedings, or final judgments exceeding $500,000, could lead to alternate conversion rights for preferred stockholders, potentially at unfavorable terms for common shareholders.
• Existing anti-takeover provisions in the Certificate of Incorporation and Bylaws could make it more difficult for stockholders to effect changes in management or corporate control.

Future Outlook

The company intends to file a registration statement on Form S-8 for shares reserved under the 2025 Employee Stock Purchase Plan. It expects to retain earnings to finance business growth and does not anticipate paying dividends in the foreseeable future. If the name change is approved, the company plans to request a new Nasdaq trading symbol (expected BXB). The proposed reverse stock split aims to increase the per-share price and bid price to regain Nasdaq listing compliance and attract institutional investors, though there is no assurance these benefits will materialize or be sustained.

Management Comments

• Amro Albanna, Chief Executive Officer and Chairman, urges stockholders to vote their shares via proxy at their earliest convenience to ensure a quorum and save the company expenses.
• The board of directors unanimously recommends a vote FOR all proposals.
• The board believes increasing the number of shares reserved under the 2021 Plan is advisable and in the best interests of the company and its stockholders to attract, motivate, and retain key employees and non-employee directors.
• The board has determined that changing the corporate name to bitXbio, Inc. is advisable and in the best interests of the company and its stockholders, as it more fully reflects the scope, direction, and strategic vision of the company, aligning with its focus on a decentralized life sciences ecosystem supported by dataand technology-driven tools.
• The board believes that enabling it to fix the specific ratio of the reverse stock split within the stated range will provide the flexibility to implement it in a manner designed to maximize anticipated benefits for stockholders, such as making the common stock more attractive to institutional investors and regaining Nasdaq compliance.

Industry Context

Aditxt operates as a life sciences platform with subsidiaries focused on immune system reprogramming (Adimune), early cancer and disease detection (Pearsanta), women's health (Adifem), and infectious diseases/immune monitoring (Adivir). The proposed name change to bitXbio, Inc. signifies a strategic shift towards integrating blockchain, Fintech, and AI technologies into its platform, aiming to enhance capitalization, transparency, and global participation. The company's efforts to maintain Nasdaq listing compliance through a reverse stock split and seeking approval for past dilutive financings reflect common challenges faced by smaller public companies in the competitive and capital-intensive life sciences sector.

Comparison to Industry Standards

• The company's need to seek stockholder approval for equity issuances under Nasdaq Marketplace Rule 5635(d) is a standard requirement for public companies undertaking significant dilutive transactions.
• The proposed reverse stock split is a common strategy employed by companies, particularly in the biotechnology and life sciences sectors, to meet exchange minimum bid price requirements and improve stock perception for institutional investors.
• The establishment of an Employee Stock Purchase Plan (ESPP) and an Omnibus Equity Incentive Plan aligns with industry standards for attracting and retaining talent through equity-based compensation, similar to practices at other publicly traded life sciences companies.

Corporate Governance

Legal Proceedings

• A Triggering Event for preferred stock conversion occurs if bankruptcy, insolvency, reorganization, or liquidation proceedings are instituted against the company or any subsidiary and not dismissed within 30 days.
• A Triggering Event also occurs if final judgments for the payment of money aggregating in excess of $500,000 are rendered against the company and/or any of its subsidiaries and are not bonded, discharged, settled, or stayed pending appeal within 30 days.

Related Party Transactions

• Amro Albanna (CEO and Chairman) beneficially owns 5 shares, including options and shares held by the Albanna Family Trust. He may be deemed to beneficially own securities held by his wife, Rowena Albanna.
• Shahrokh Shabahang (D.D.S., MS, Ph.D.) beneficially owns 6 shares, including options and shares held by the Shabahang-Hatami Family Trust.
• Corinne Pankovcin beneficially owns 3 shares, issuable pursuant to fully vested options.
• Rowena Albanna (Chief Operating Officer) beneficially owns 8 shares, including direct holdings and options. She may be deemed to beneficially own securities held by her husband, Amro Albanna.
• Brian Brady beneficially owns 5 shares, including direct holdings and options.
• Christopher J. Porcelli (General Counsel) beneficially owns less than 1% of common stock.
• Thomas J. Farley (Chief Financial Officer) beneficially owns 3 shares, including direct holdings and options.
• Charles Nelson beneficially owns 2 shares, including shares held by Siu Kim Athle International, LLC, over which he has control, and options.
• All directors and executive officers as a group (9 persons) beneficially own less than 1% of the outstanding common stock.

Stakeholder Impact

• **Shareholders**: Face significant potential dilution from the conversion of preferred stock and exercise of warrants, as well as from the expanded equity incentive plan. The proposed reverse stock split aims to improve Nasdaq compliance and stock attractiveness but carries risks of negative perception and uncertain long-term price stability. Voting rights are exercised on key corporate actions, but anti-takeover provisions may limit influence on control.
• **Employees**: Will benefit from the proposed 2025 Employee Stock Purchase Plan (ESPP) allowing discounted stock purchases and the increased share pool for the 2021 Omnibus Equity Incentive Plan, enhancing compensation and alignment with company performance.
• **Management/Directors**: Are eligible to receive equity awards under the 2021 Plan, giving them a direct interest in its approval. The board gains discretionary authority over the reverse stock split and the name change, providing flexibility in corporate strategy and market positioning.
• **Creditors**: Holders of Series A-1 and C-1 Preferred Stock have liquidation preferences (125% of conversion amount or converted value) and specific 'Triggering Event' clauses that could lead to alternate conversion rights or mandatory redemption if the company defaults on significant indebtedness or faces bankruptcy/judgments.

Next Steps

• Stockholders will vote on the proposals at the Special Meeting on January 30, 2026.
• The company will disclose final voting results in a Current Report on Form 8-K within four business days after the Special Meeting.
• If the Name Change Proposal is approved and the Board decides to proceed, the company will file a Certificate of Amendment and request a new Nasdaq trading symbol (expected BXB).
• If the Reverse Split Proposal is approved, the board has the discretion to effect the reverse stock split within one year.
• If the ESPP is approved, the company intends to file a registration statement on Form S-8 for the reserved shares.

Key Dates

Recommendation

The company is seeking shareholder approval for a series of proposals that, while presented as beneficial for long-term strategy and compliance, collectively signal underlying financial distress and significant risks for common shareholders. The need for a reverse stock split (up to 1:250) to maintain Nasdaq listing, coupled with the approval of past highly dilutive preferred stock and warrant issuances (even with adjusted conversion prices of $1.582 to $4.44 per share, these were likely issued at a discount to market at the time of agreement), indicates a severely challenged stock valuation. The potential for further dilution from these instruments and expanded employee equity plans, combined with the inherent negative perception of reverse stock splits, suggests continued downward pressure or volatility on the common stock. A seasoned investor would likely view these actions as defensive maneuvers rather than indicators of robust growth, warranting a 'sell' recommendation due to high risk and uncertain upside.

Keywords

Reverse Stock Split, Nasdaq Compliance, Equity Dilution, Preferred Stock Conversion, Warrants, Employee Stock Purchase Plan, Equity Incentive Plan, Corporate Name Change, Biotechnology, Life Sciences, Blockchain, Fintech, AI